Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Patricia Drake to lead commercial at Innoviva’s specialty unit

Plus: Thomas Mehrling name CEO of Swiss biotech Release, and Tenaya CSO Hoey stepping down

By Gunjan Ohri, Data Content Analyst
July 2, 2024 12:12 AM UTC

Innoviva Inc. (NASDAQ:INVA) hired Patricia Drake as chief commercial officer of subsidiary Innoviva Specialty Therapeutics Inc., which markets infectious disease and critical care products. Drake, a longtime veteran of Merck & Co. Inc. (NYSE:MRK), was most recently SVP, CCO at Trevena Inc. (NASDAQ:TRVN). 

Switzerland-based Release Therapeutics S.A. named Thomas Mehrling as CEO. Mehrling was CEO of Laevoroc Oncology AG, a company he founded. Release is developing a technology capable of delivering therapeutic proteins through the blood-brain barrier to treat CNS disorders. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Innoviva Inc.

Tenaya Therapeutics Inc.